StreetAlpha.app
Home › Stocks › ANIP

Ani Pharmaceuticals Inc (ANIP)

Healthcare
$68.55
▼ −0.84%
LAST CLOSE · NOV 20

ANI Pharmaceuticals develops, makes, and sells prescription medicines, including rare disease, brand name, and generic drugs. It last closed at $68.55 on Nov 20, down 0.84% on the day. The next earnings report for ANIP is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, ANIP reported EPS of $1.51 on revenue of $290.8M, with revenue up 27.6% from a year ago. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months ANIP insiders bought $0 of stock on the open market and sold $14.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is ANIP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANIP.

Key Stats

Last 12 months
Results
Revenue
$1.0B
+25.9% vs a year ago
Net income
$116.8M
+188.0% vs a year ago
EPS (diluted)
$5.03
+214.4% vs a year ago
Free cash flow
$205.3M
19.7% margin
Balance sheet
Cash & equivalents
$420.8M
At Sep 30
Debt
$297.7M
At Sep 30
Shareholder equity
$637.1M
Buybacks
$19.2M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $216.1M$216.1MFY2021FY2022: $316.4M$316.4MFY2022FY2023: $486.8M$486.8MFY2023FY2024: $614.4M$614.4MFY2024FY2025: $883.4M$883.4MFY2025

From ANIP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$1.51
Quarter ended Sep 2026
Year ago EPS
$1.13
+33.6% on a GAAP basis
Revenue
$290.8M
+27.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.55Dec '24Mar 2025: $0.69Mar '25Jun 2025: $0.36Jun '25Sep 2025: $1.13Sep '25Dec 2025: $1.17Dec '25Mar 2026: $1.28Mar '26Jun 2026: $1.05Jun '26Sep 2026: $1.51Sep '26Latest $1.51
Revenue by quarter
Dec 2024: $190.6MDec '24Mar 2025: $197.1MMar '25Jun 2025: $211.4MJun '25Sep 2025: $227.8MSep '25Dec 2025: $247.1MDec '25Mar 2026: $237.5MMar '26Jun 2026: $266.0MJun '26Sep 2026: $290.8MSep '26Latest $290.8M
How ANIP moved after its last 8 reports
Average move the session after a report ±2.3%
Nov 5, 2026Time not announced−2.8%
Aug 7, 2026Time not announced−5.3%
May 8, 2026Time not announced−2.4%
Feb 27, 2026Time not announced−4.2%
Jan 12, 2026After the close−2.5%
Nov 7, 2025Time not announced+0.2%
Sep 8, 2025Time not announced−0.2%
Jul 23, 2025Time not announced+0.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ANIPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANIP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANIP

Technical Analysis

ANIP · as of the Nov 20 close · updated each morning
Downtrend

The stock is 3% below its 20 day and 5% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot S1 at $67.82, and the nearest resistance the Pivot at $69.01.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 3.3%/day
Key levels
$87.7652 week high+28.0%
$76.74200 day average+11.9%
$74.90100 day average+9.3%
$72.2450 day average+5.4%
$72.24Swing high (Nov 11)+5.4%
$70.7520 day average+3.2%
$69.74Pivot R1+1.7%
$69.01Pivot+0.7%
$68.55Last close
$67.82Pivot S1−1.1%
$67.1452 week low−2.1%
$67.14Swing low (Nov 6)−2.1%
Indicators
RSI (14)41.30Middle of its rangeNeutral
MACD-0.71Below its signal lineBearish
Stochastic29.1Middle of its rangeNeutral
ADX (14)9.2No clear trend
Williams %R-84.0Oversold below −80, overbought above −20Oversold
CCI (20)-124.0Oversold below −100, overbought above 100Oversold
Rate of change+1.7%Change over 10 sessionsBullish
ATR (14)$2.28Typical daily range, 3.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANIP

What happened before

See how ANIP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ANIP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANIP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANIPHow many large options trades hit ANIP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANIP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲166 buying vs 135 selling
  • ▲Shares held by funds +2.9%
  • ▼Funds holding -16
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding294310−5.2%
In funds' top 1003−100.0%
Held by funds–––
New / increased38 / 12850 / 120−2.4%
Reduced / sold out81 / 5488 / 26+18.4%
Put/call ratio1.44––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANIP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANIP Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$14.0M43 sales · 11 insiders
46% of the selling was under pre-arranged trading plans.
2025-12 sold $313K2026-01 sold $42K2026-02 sold $1.3M2026-03 sold $2.7M2026-04 sold $39K2026-05 sold $5.7M2026-06 sold $707K2026-07 sold $558K2026-08 sold $890K2026-09 sold $698K2026-10 sold $633K2026-11 sold $420KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Nikhil LalwaniPresident & CEOSale plan5,400$71.22$385K
Nov 13Meredith CookSr. Vp, General Counsel & Sec.Sale plan500$70.80$35K
Oct 29Stephen P. CareySVP & CFOSale plan2,850$72.87$208K
Oct 15Nikhil LalwaniPresident & CEOSale plan5,400$71.89$388K
Oct 13Meredith CookSr. Vp, General Counsel & Sec.Sale plan500$73.59$37K
Sep 29Stephen P. CareySVP & CFOSale plan2,850$73.00$208K
Every insider buy and sale for ANIP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANIP insider trades →

From SEC Form 4 filings by ANIP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIP is in one of them and how their past ANIP trades turned out.

ANIP in the AI portfolios
Loading…

ANIP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANIP in an article yet. Here's the latest on the wider market.

ANIP in the news

About Ani Pharmaceuticals

ANI Pharmaceuticals is a biopharmaceutical company based in Princeton, New Jersey. It develops, manufactures, and sells prescription medicines in three areas: rare disease treatments, brand name products, and generic drugs. Its rare disease products include Purified Cortrophin Gel and the ILUVIEN and YUTIQ eye implants, which treat conditions such as diabetic macular edema and uveitis. The company makes its products at its own plants in Minnesota and New Jersey and sells them to patients, physicians, and specialty pharmacies.

Headquarters
Princeton, NJ